Bolt Biotherapeutics Income Statement (2019-2025) | BOLT

Income Statement Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.16M0.07M0.75M0.51M0.81M1.39M2.11M1.41M1.83M1.43M2.53M2.09M5.27M1.27M1.14M1.22M1.80M2.17M
Operating items
Research & Development 6.79M9.17M9.54M14.86M19.71M19.34M22.48M18.39M18.92M18.97M16.84M14.62M15.64M14.95M16.32M16.53M15.43M13.79M11.72M9.51M7.50M6.54M
Selling, General & Administrative 2.12M2.01M2.87M2.06M4.05M4.94M5.10M6.30M5.53M5.49M5.61M5.62M5.62M5.76M5.53M5.84M4.87M3.80M3.95M3.83M3.52M3.34M
Restructuring Costs 3.56M-0.22M
Other Operating Expenses 1.47M
Operating Expenses 8.91M11.18M12.40M16.92M23.76M24.28M27.58M24.69M24.45M24.46M22.45M20.24M21.27M20.71M21.86M22.37M23.87M17.58M16.92M13.34M11.01M9.87M
Operating Income -8.74M-11.11M-12.40M-16.92M-23.76M-23.53M-27.07M-23.88M-23.06M-22.35M-21.04M-18.41M-19.83M-18.18M-19.77M-17.09M-22.60M-16.44M-16.92M-12.12M-9.21M-7.70M
EBIT -8.74M-11.11M-12.40M-16.92M-23.76M-23.53M-27.07M-23.88M-23.06M-22.35M-21.04M-18.41M-19.83M-18.18M-19.77M-17.09M-22.60M-16.44M-16.92M-12.12M-9.21M-7.70M
Non-operating items
Interest & Investment Income 0.11M0.05M0.02M0.01M0.18M0.13M-0.08M0.20M0.40M0.59M1.04M1.44M1.77M1.93M1.86M1.61M1.40M1.27M0.98M1.05M0.60M0.48M
Non Operating Income 0.11M0.05M2.40M-14.11M0.18M0.13M-0.08M0.20M0.40M0.59M1.04M1.44M1.77M1.93M1.86M6.28M1.40M1.27M0.98M1.07M0.65M0.56M
Net income details
EBT -8.63M-11.06M-12.38M-16.91M-23.59M-23.39M-27.16M-23.68M-22.66M-21.76M-20.00M-16.98M-18.06M-16.26M-17.90M-15.49M-21.20M-15.18M-15.94M-11.06M-8.61M-7.23M
Profit After Tax -8.63M-11.06M-10.00M-31.04M-23.59M-23.39M-27.16M-23.68M-22.66M-21.76M-20.00M-16.98M-18.06M-16.26M-17.90M-10.81M-21.20M-15.18M-15.94M-11.04M-8.56M-7.14M
Income from Continuing Operations -8.63M-11.06M-12.38M-16.91M-23.59M-23.39M-27.16M-23.68M-22.66M-21.76M-20.00M-16.98M-18.06M-16.26M-17.90M-15.49M-21.20M-15.18M-15.94M-11.06M-8.61M-7.23M
Consolidated Net Income -8.63M-11.06M-12.38M-16.91M-23.59M-23.39M-27.16M-23.68M-22.66M-21.76M-20.00M-16.98M-18.06M-16.26M-17.90M-15.49M-21.20M-15.18M-15.94M-11.06M-8.61M-7.23M
Income towards Parent Company -8.63M-11.06M-12.38M-16.91M-23.59M-23.39M-27.16M-23.68M-22.66M-21.76M-20.00M-16.98M-18.06M-16.26M-17.90M-15.49M-21.20M-15.18M-15.94M-11.06M-8.61M-7.23M
Net Income towards Common Stockholders -8.63M-11.06M-12.38M-16.91M-23.59M-23.39M-27.16M-23.68M-22.66M-21.76M-20.00M-16.98M-18.06M-16.26M-17.90M-15.49M-21.20M-15.18M-15.94M-11.06M-8.61M-7.23M
Additional items
EPS (Basic) -4.16-5.29-4.73-14.70-0.64-0.63-0.73-0.64-0.61-0.58-0.53-0.45-0.48-0.43-0.47-0.28-11.12-7.93-0.42-0.29-4.46-3.72
EPS (Weighted Average and Diluted) -0.63-0.73-0.64-0.61-0.58-0.53-0.45-0.48-0.43-0.47-0.28-11.12-7.93-0.42-0.29-4.46-3.72
Shares Outstanding (Weighted Average) 0.02M0.03M37.21M33.20M37.13M37.29M37.45M37.36M37.68M37.75M37.87M37.81M38.07M1.91M1.91M38.18M38.34M1.92M1.92M
Shares Outstanding (Diluted Average) 37.21M33.20M37.13M37.29M37.45M37.36M37.68M37.75M37.87M37.81M38.07M1.91M1.91M38.18M38.34M1.92M1.92M
EBITDA -8.64M-11.05M-10.00M-31.04M-23.54M-23.41M-27.44M-24.75M-23.07M-21.66M-19.21M-16.30M-18.05M-16.20M-17.69M-10.88M-21.20M-14.93M-16.04M-11.10M-8.61M-7.15M
Shares Outstanding 1.92M1.94M1.94M2.10M2.13M36.33M37.19M37.25M37.40M37.47M37.64M37.66M37.80M37.81M37.95M37.97M1.91M1.91M1.91M1.91M1.92M1.92M1.92M1.92M